Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (also referenced as Quoin Pharmaceuticals, Ltd. in metadata) for the month of June 2017. The filing reports on a court-approved arrangement between the Company and its security holders approved by the Central District Court in Lod on May 29, 2017.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a corporate restructuring event regarding warrant terms and stock exchange listing status.
Material Changes
- Warrant Exercise Period: Extended to 80 days from the Court's approval, ending on August 17, 2017.
- Warrant Exercise Price: Reduced from NIS 1.85 per warrant to NIS 1.20 per warrant.
- Listing Status: Ordinary Shares are scheduled to be delisted from the Tel Aviv Stock Exchange, subject to Board approval. American Depositary Receipts (ADRs) will continue to trade on NASDAQ.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of the court-approved arrangement. The primary contingency noted is that the delisting from the Tel Aviv Stock Exchange is subject to approval by the Company's board of directors. No specific forward-looking financial guidance or risk factors beyond the restructuring were disclosed in this text.
Investor Verification Checklist
- Confirm the final Board of Directors' approval regarding the delisting from the Tel Aviv Stock Exchange.
- Verify the exact number of warrants outstanding to assess the dilution impact of the reduced exercise price (NIS 1.20).
- Monitor the trading status of ADRs on NASDAQ to ensure continuity during the transition.
- Review subsequent filings for any financial impact resulting from the warrant modifications.